Travere Therapeutics entered June 2026 with two developments in the space of three days that reshaped its near-term picture. On June 1, the San Diego biopharmaceutical company signed a licensing agreement with Everest Medicines for civorebrutinib, a covalent reversible BTK inhibitor, adding a new immune-targeting mechanism to a pipeline built around rare renal and metabolic conditions. Three days later, the company presented long-term data from the open-label extension of its Phase 3 DUPLEX study at the European Renal Association Congress in Glasgow, showing durable responses for its lead drug FILSPARI in focal segmental glomerulosclerosis.
Armistice Capital disclosed ownership of 4,897,417 Travere shares, or 5.27 percent of the class, in a Schedule 13G filed May 15. Norges Bank, First Trust Advisors, and Qube Research and Technologies were among other institutional investors that recently adjusted positions in the stock.
FILSPARI’s Full Approval and the FSGS Opportunity
The Glasgow data extended a milestone reached in April, when the FDA granted FILSPARI full approval for focal segmental glomerulosclerosis, making it the first and only medicine approved for the disease. The indication covers patients aged 8 and older without nephrotic syndrome. Travere estimates roughly 30,000 people with FSGS in the United States could be eligible, and Chief Executive Eric Dube has said the FSGS approval expands FILSPARI’s total eligible population to approximately 100,000.
In the double-blind portion of the DUPLEX study, 18.5 percent of FILSPARI patients reached complete remission and 69.0 percent achieved partial remission. In the open-label extension, those figures improved to 37.5 percent complete remission and 87.5 percent partial remission. Patients who had been on irbesartan during the double-blind phase and then switched to FILSPARI recorded proteinuria reductions similar to those who had started on the drug from the beginning, a finding that supports the drug’s activity regardless of prior treatment history.
FILSPARI reached the market in 2023 under accelerated approval for IgA nephropathy and converted to full approval for that indication in 2024. Product sales rose 144 percent to $410 million in 2025, with the United States contributing $322 million. The drug is now the most commonly prescribed FDA-approved therapy for IgA nephropathy. Analysts have estimated the FSGS opportunity alone could approach $1 billion in annual revenue.
The BTK Inhibitor Deal
The Everest Medicines agreement adds civorebrutinib on terms that call for a $112.5 million upfront payment, up to roughly $1.03 billion in milestone payments, and tiered royalties. Both companies agreed to a 10-year non-compete on rival BTK products.
Travere leads development and commercialization of civorebrutinib outside China and certain East and Southeast Asian countries, the territories retained by Everest. The candidate is being studied in immune-mediated kidney conditions including primary membranous nephropathy and immune-mediated focal segmental glomerulosclerosis. BTK inhibition disrupts B-cell signaling that drives antibody production in those conditions, adding a mechanistic dimension to the Travere pipeline that FILSPARI does not cover.
The Pipeline Beyond FILSPARI
Travere is also developing pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria, a genetic metabolic disorder caused by cystathionine beta synthase deficiency. The program holds Breakthrough Therapy, Fast Track, and orphan drug designations from the FDA, and the company has guided to topline data in 2026. Together with civorebrutinib, the candidates give Travere multiple programs in rare renal and metabolic conditions where treatment options remain scarce.
Market and Analyst Response
Travere shares reached a 52-week high of $49.00 on June 9, following a run that began with first-quarter 2026 earnings reported May 4. Revenue of $127.2 million, up 55.6 percent year over year, and earnings of $0.05 per share against a consensus estimate of a $0.24 loss provided the catalyst.
TD Cowen raised its price target to $60 on May 5. H.C. Wainwright moved to $67 on June 2. Wedbush reaffirmed an outperform rating with a $55 target on June 3. The consensus rating stood at moderate buy, with 10 buy ratings, two holds, and one sell, and an average price target of $48.92.